

Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
(Last updated June 3, 2021; last reviewed June 3, 2021) (Page 1 of 1)

Generic Name (Abbreviation) <i>Trade Name</i>	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Fostemsavir (FTR) <i>Rukobia</i>	<ul style="list-style-type: none"> 600-mg extended-release tablets 	<ul style="list-style-type: none"> FTR 600 mg PO twice daily 	11 hours	Hydrolysis (esterases), CYP3A4	Nausea QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval. Transaminase elevation; transient bilirubin elevation Sleep disturbance, dizziness

Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval